Literature DB >> 27405316

A Novel Model of Dexamethasone-Induced Hypertension: Use in Investigating the Role of Tyrosine Hydroxylase.

Alexandra E Soto-Piña1, Cynthia Franklin2, C S Sheela Rani2, Helmut Gottlieb2, Carmen Hinojosa-Laborde2, Randy Strong2.   

Abstract

Our objective was to study hypertension induced by chronic administration of synthetic glucocorticoid, dexamethasone (DEX), under nonstressful conditions and examine the role of catecholamine biosynthesis. To achieve this, we did the following: 1) used radiotelemetry to record mean arterial pressure (MAP) and heart rate (HR) in freely moving rats, and 2) administered different doses of DEX in drinking water. To evaluate the involvement of tyrosine hydroxylase (TH), the rate-limiting step in catecholamine biosynthesis, we treated rats with the TH inhibitor, α-methyl-para-tyrosine (α-MPT), for 3 days prior to administration of DEX and assessed TH mRNA and protein expression by quantitative real-time polymerase chain reaction and Western blot in the adrenal medulla. We observed a dose-dependent elevation in blood pressure with a DEX dose of 0.3 mg/kg administered for 10 days, significantly increasing MAP by +15.0 ± 1.1 mm Hg, while concomitantly reducing HR. Although this DEX treatment also significantly decreased body weight, pair-fed animals that showed similar decreases in body weight due to lowered food intake were not hypertensive, suggesting that body weight changes may not account for DEX-induced hypertension. Chronic DEX treatment significantly increased the TH mRNA and protein levels in the adrenal medulla, and α-MPT administration not only reduced DEX pressor effects, but also inhibited TH (serine(40)) phosphorylation. Our study thus validates a novel model to study hypertension induced by chronic intake of DEX in freely moving rats not subject to the confounding factors of previous models and establishes its dependence on concomitant activation of peripheral catecholamine biosynthesis.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27405316     DOI: 10.1124/jpet.116.234005

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  3 in total

1.  Striatal miR-183-5p inhibits methamphetamine-induced locomotion by regulating glucocorticoid receptor signaling.

Authors:  Sang-Hoon Song; Won-Jun Jang; Eun Young Jang; Oc-Hee Kim; Haesoo Kim; Taekwon Son; Dong-Young Choi; Sooyeun Lee; Chul-Ho Jeong
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

2.  Hypoglycemic Properties of the Aqueous Extract from the Stem Bark of Ceiba pentandra in Dexamethasone-Induced Insulin Resistant Rats.

Authors:  Christian Kuété Fofié; Elvine Pami Nguelefack-Mbuyo; Nole Tsabang; Albert Kamanyi; Télesphore Benoît Nguelefack
Journal:  Evid Based Complement Alternat Med       Date:  2018-09-16       Impact factor: 2.629

3.  Dexamethasone Causes Hypertension in Rats Even Under Chemical Blockade of Peripheral Sympathetic Nerves.

Authors:  Alexandra E Soto-Piña; Cynthia Franklin; C S Sheela Rani; Elizabeth Fernandez; Elías Cardoso-Peña; Alejandra D Benítez-Arciniega; Helmut Gottlieb; Carmen Hinojosa-Laborde; Randy Strong
Journal:  Front Neurosci       Date:  2019-12-06       Impact factor: 4.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.